Company Analysis West Pharmaceutical Services, Inc.
1. Summary
Advantages
- The stock's return over the last year (34.44%) is higher than the sector average (-0.9479%).
- Current debt level 8.3% is below 100% and has decreased over 5 years from 11.67%.
- The company's current efficiency (ROE=17.71%) is higher than the sector average (ROE=-74.13%)
Disadvantages
- Price (273.63 $) is higher than fair price (99.09 $)
- Dividends (0.3182%) are below the sector average (1.36%).
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| West Pharmaceutical Services, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0.4% | 0% | 1.2% |
| 90 days | -1.2% | 3.7% | 3.1% |
| 1 year | 34.4% | -0.9% | 17.1% |
WST vs Sector: West Pharmaceutical Services, Inc. has outperformed the "Healthcare" sector by 35.39% over the past year.
WST vs Market: West Pharmaceutical Services, Inc. has outperformed the market by 17.31% over the past year.
Stable price: WST is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: WST with weekly volatility of 0.6623% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (273.63 $) is higher than the fair price (99.09 $).
Price is higher than fair: The current price (273.63 $) is 63.8% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (49.19) is lower than that of the sector as a whole (142.19).
P/E vs Market: The company's P/E (49.19) is lower than that of the market as a whole (73.05).
5.2.1 P/E Similar companies
5.3. P/BV
P/BV vs Sector: The company's P/BV (9.03) is lower than that of the sector as a whole (18.07).
P/BV vs Market: The company's P/BV (9.03) is lower than that of the market as a whole (20.45).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (8.38) is lower than that of the sector as a whole (14.7).
P/S vs Market: The company's P/S indicator (8.38) is lower than that of the market as a whole (30.65).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (32.34) is lower than that of the sector as a whole (61.62).
EV/Ebitda vs Market: The company's EV/Ebitda (32.34) is lower than that of the market as a whole (36.12).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -5.11% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-5.11%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-74.62%).
6.4. ROE
ROE vs Sector: The company's ROE (17.71%) is higher than that of the sector as a whole (-74.13%).
ROE vs Market: The company's ROE (17.71%) is lower than that of the market as a whole (51.58%).
6.6. ROA
ROA vs Sector: The company's ROA (13.19%) is higher than that of the sector as a whole (6.62%).
ROA vs Market: The company's ROA (13.19%) is higher than that of the market as a whole (11.19%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (28.73%) is higher than that of the sector as a whole (21.38%).
ROIC vs Market: The company's ROIC (28.73%) is lower than that of the market as a whole (45.09%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0.3182% is below the average for the sector '1.36%.
8.2. Stability and increase in payments
Dividend stability: The company's dividend yield 0.3182% has been steadily paid over the past 7 years, DSI=0.93.
Weak dividend growth: The company's dividend yield 0.3182% has been growing weakly or stagnant over the past 5 years. Growth over only 3 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (12%) are at an uncomfortable level.
9. Insider trades
9.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
9.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 18.02.2025 | Green Eric Mark President, CEO and Board Chair |
Purchase | 211 | 519 271 | 2 461 |
| 18.02.2025 | Witherspoon Charles VP & Treasurer |
Purchase | 211 | 13 926 | 66 |
| 18.02.2025 | Winters Chad VP, Chief Accounting Officer |
Purchase | 211 | 17 302 | 82 |
| 18.02.2025 | Favorite Annette F Sr. VP & Chief HR Officer |
Purchase | 211 | 51 906 | 246 |
| 07.05.2024 | Green Eric Mark President, CEO and Board Chair |
Sale | 366.65 | 24 198 900 | 66 000 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
